What type of study is this?

This is a Pre-Registered Trial study.

December 8, 2025Blood

Impact of long-term luspatercept treatment on iron parameters in patients with transfusion-dependent and non-transfusion-dependent β-thalassemia: Results from the phase 3b long-term follow-up study

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows long-term luspatercept reduces iron overload in β-thalassemia, indicating benefits for treatment.

Long-term luspatercept treatment in β-thalassemia reduces iron overload effectively.
Patients with β-thalassemia experienced significant drops in iron parameters, with stable cardiac markers.
Analysis from phase 3b LTFU study details the durability of iron level reductions across multiple evaluations.
These findings suggest that ongoing luspatercept treatment benefits both transfusion-dependent and non-transfusion-dependent populations.

Martín-Regueira et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows long-term luspatercept reduces iron overload in β-thalassemia, indicating benefits for treatment.

Long-term luspatercept treatment in β-thalassemia reduces iron overload effectively.
Patients with β-thalassemia experienced significant drops in iron parameters, with stable cardiac markers.
Analysis from phase 3b LTFU study details the durability of iron level reductions across multiple evaluations.
These findings suggest that ongoing luspatercept treatment benefits both transfusion-dependent and non-transfusion-dependent populations.

Martín-Regueira et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark